A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Neutra Corp. was incorporated in Nevada on January 11, 2011 to market and participate in the nutraceutical space by bringing products derived from all natural and organic origins. On August 16, 2019, Neutra Corp. reincorporated in Wyoming. Along with participating in the actual nutraceutical products, we plan to research and bring new technology to the nutraceutical space. Nutraceutical natural medicine is an alternative system that focuses on natural remedies and the body’s vital ability to heal and maintain itself. One of the nutraceutical sub-markets is the new thriving medical cannabis market, in which we intend to participate. We intend to entrust the manufacturing to a nutraceutical contractor to private label all of our products and to sell them under our unique brand. We have established a fiscal year end of January 31.
| Metric | TTM | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 17K | 0 | - | - | 0 |
| Net Income | -475K | -577K | -742K | -581K | -696K |
| EPS | $-0.00 | $-0.00 | - | $0.00 | $0.00 |
| Free Cash Flow | 0 | -193K | -446K | -609K | -182K |
| ROIC | -743.2% | 0.0% | -352.1% | -198.2% | 0.0% |
| Gross Margin | 46.2% | 0.0% | - | - | 0.0% |
| Debt/Equity | 0.00 | 0.00 | -1.10 | -1.20 | 0.00 |
| Dividends/Share | $0.00 | $0.00 | - | - | $0.00 |
| Operating Income | -253K | -298K | -584K | -479K | -394K |
| Operating Margin | -1457.1% | 0.0% | - | - | 0.0% |
| ROE | 0.0% | 0.0% | - | - | 0.0% |
| Shares Outstanding | 2,918M | 2,918M | - | - | - |
| Metric | 2020 | 2021 | |||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0 | N/A | N/A | 0 | 17K |
| Gross Margin | 0.0% | N/A | N/A | 0.0% | 46.2% |
| R&D | N/A | N/A | N/A | N/A | N/A |
| SG&A | 401K | 415K | 508K | 228K | 193K |
| EBIT | -394K | -479K | -584K | -298K | -253K |
| Op. Margin | 0.0% | N/A | N/A | 0.0% | -1457.1% |
| Net Income | -696K | -581K | -742K | -577K | -475K |
| Net Margin | 0.0% | N/A | N/A | 0.0% | -2730.2% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||
| ROIC | 0.0% | -198.2% | N/M | 0.0% | N/M |
| ROE | 0.0% | N/A | N/A | 0.0% | 0.0% |
| ROA | 0.0% | -304.4% | -461.4% | 0.0% | -1762.8% |
| Cash Flow | |||||
| Op. Cash Flow | -182K | -412K | -406K | -153K | -10K |
| Free Cash Flow | -182K | -609K | -446K | -193K | 0 |
| Owner Earnings | -182K | -443K | -514K | -341K | -71K |
| CapEx | 0 | 196K | 40K | 40K | 0 |
| Maint. CapEx | 0 | 31K | 108K | 187K | 62K |
| Growth CapEx | N/A | 166K | 0 | 0 | 0 |
| D&A | 0 | 31K | 108K | 187K | 62K |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | -154K | 0 | N/A | N/A | 53K |
| Cash & Equiv. | 177K | 23K | 1K | 2K | 1K |
| Long-Term Debt | N/A | N/A | N/A | N/A | 54K |
| Debt/Equity | 0.00 | -1.20 | -1.10 | 0.00 | 0.00 |
| Interest Coverage | -1.2 | -3.9 | -9.6 | -4.8 | -4.8 |
| Equity | 0 | -967K | -1.3M | 0 | -936K |
| Total Assets | 0 | 191K | 131K | 0 | 27K |
| Total Liabilities | 1.0M | 1.0M | 1.2M | 814K | 963K |
| Intangibles | 0 | N/A | N/A | 0 | 0 |
| Retained Earnings | -9.6M | -10M | -11M | -11M | -12M |
| Working Capital | -849K | -977K | -1.2M | -734K | -889K |
| Current Assets | 182K | 25K | 3K | 26K | 19K |
| Current Liabilities | 1.0M | 1.0M | 1.2M | 760K | 909K |
| Per Share Data | |||||
| EPS | 0.00 | 0.00 | N/A | -0.00 | -0.00 |
| Owner EPS | N/A | N/A | N/A | -0.00 | -0.00 |
| Book Value | 0.00 | -0.00 | -0.00 | 0.00 | -0.00 |
| Cash Flow/Share | N/A | N/A | N/A | -0.00 | -0.00 |
| Dividends/Share | 0.00 | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | N/A | N/A | N/A | 2.9B | 2.9B |
| Valuation | |||||
| P/E Ratio | N/A | N/A | N/A | N/A | -1.2 |
| P/FCF | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | 33.5 |
| FCF Yield | N/A | -9.2% | -18.4% | N/A | N/A |
| Market Cap | 0 | 6.6M | 2.4M | 0 | 584K |
| Avg. Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NEUTRA CORP. passes 0 of 9 quality checks, indicating weak fundamentals.
NEUTRA CORP. (NTRR) has a 5-year average return on invested capital (ROIC) of -66.1%. This is below average and may indicate limited pricing power.
NEUTRA CORP. (NTRR) has a market capitalization of $584K. It is classified as a small-cap stock.
NEUTRA CORP. (NTRR) does not currently pay a regular dividend.
NEUTRA CORP. (NTRR) operates in the Medicinal Chemicals & Botanical Products industry, within the Healthcare sector.
NEUTRA CORP. (NTRR) generated $-193 thousand in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
NEUTRA CORP. (NTRR) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
NEUTRA CORP. (NTRR) reported earnings per share (EPS) of $-0.00 in its most recent fiscal year.
The Ledger Terminal provides 4 years of financial data for NEUTRA CORP. (NTRR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
No recent press releases.